Observational studyRMD open2026
Clinical course, complications and treatment outcomes in Still's disease: a 10-year single-centre cohort study.
Observational study in RMD open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Distinct cytokine and chemokine alterations in bronchoalveolar fluid from patients with systemic juvenile idiopathic arthritis associated lung disease (SJIA-LD).Arthritis research & therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the long-term outcomes, clinical phenotypes and factors associated with complications in Still's disease (systemic juvenile idiopathic arthritis) based on data from a 10-year single-centre cohort.
methodsThis retrospective observational study included 110 patients with Still's disease/systemic juvenile idiopathic arthritis (sJIA) followed between 2015 and 2025 at a tertiary paediatric rheumatology centre. Demographic, clinical and laboratory parameters were analysed for associations with macrophage activation syndrome (MAS), interstitial lung disease (ILD), disease course and treatment outcomes. Statistical analyses included non-parametric tests, correlation analyses and logistic regression.
resultsMAS occurred in 36.7% of patients, nearly half at disease onset. Serositis at diagnosis was associated with subsequent MAS, while low haemoglobin and erythrocyte sedimentation rate reflected concurrent MAS features. ILD was observed in 8.2% of patients and was strongly associated with MAS and a polycyclic disease course. Older age at onset and the presence of rash were independently associated with a polycyclic course. Early anakinra initiation was more frequent in severe cases but was not independently associated with improved long-term outcomes.
conclusionThis 10-year cohort demonstrates marked heterogeneity in Still's disease/sJIA. MAS and ILD frequently co-occur and indicate a more aggressive course. Clinical features such as serositis may help identify patients at risk, whereas laboratory abnormalities should be interpreted in the context of active MAS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.